Kwality Pharmaceuticals - Extremely cheap pharma stock (P/E less than 3x)

Stock Opportunities Untested - but worth a good look
69

Institutions have started to invest.

First institutional investment in Kwality Pharma by Ark Global Emerging Companies. As more institutions including mutual funds enter stock will be rerated.
09 Jan 2026: Deepak Bansal Sale 69,3531,122 Ark Global Emerging Companies, Lp B76,4001,130

With mcap at almost 1,500 cr hopefully mutual funds start buying leading to rerating of stock.

2 Likes
70

can you explain the logic behind this figure

72

this may be correct as price has run up a lot in past few years.

however for medium to long term company is going to do well. my estimates of numbers based on management guidance are given below. With every quarterly result price should go up. Price could be higher if multiples are higher than 22 which i have assumed.

Base case in INR Cr
With Hormone plant;
Without Biologics Mar-25 Mar-26 Mar-27 Mar-28 Mar-29 Mar-30
Sales 370 500 650 850 1020 1224
Growth 20% 35% 30% 31% 20% 20%
Expenses 290 389 505 631 751 894
Operating Profit 80 111 145 219 269 330
Operating Margin % 22% 22% 22% 26% 26% 27%
Other Income 2 2 2 2 2 2
Depreciation 18 18 18 18 18 18
Interest 10 10 12 15 15 15
Profit before tax 54 85 117 187 238 299
Tax 13 21 29 47 59 75
Net profit 40 64 87 140 178 224
Net Margin % 11% 13% 13% 17% 17% 18%
EPS 38.6 61.6 84.0 135.0 171.5 215.7
Price to earning 22.5 22 22 22 22 20
Price 869 1,355 1,848 2,971 3,773 4,314
1 Like
73

Thanks for sharing this. But one sincere request, PLEASE put conservative growth of say 15% and OPM of 20% and PE of 20 and then see how the market cap evovles.

74

Sales and margins numbers have been taken as per guidance.

have reduced multiple to 20, increased depreciation. numbers are not too different.

Base case in INR Cr
With Hormone plant
Without Biologics Mar-25 Mar-26 Mar-27 Mar-28 Mar-29 Mar-30
Sales 370 500 650 850 1020 1224
Growth 20% 35% 30% 31% 20% 20%
Expenses 290 389 505 631 751 894
Operating Profit 80 111 145 219 269 330
Operating Margin % 22% 22% 22% 26% 26% 27%
Other Income 2 2 2 2 2 2
Depreciation 18 20 30 35 35 35
Interest 10 10 12 15 15 15
Profit before tax 54 83 105 170 221 282
Tax 13 21 26 43 55 71
Net profit 40 63 78 128 166 212
Net Margin % 11% 13% 12% 15% 16% 17%
EPS 38.6 60.1 75.4 122.8 159.2 203.4
Price to earning 22.5 22 20 20 20 20
Price 869 1,323 1,507 2,456 3,185 4,069
2 Likes
75

Thanks once again. But of course, we can allow some margin of safety [MOS] (maybe 25% less) for sales and margins and calculate accordingly, if you don’t mind. Management will always try to give higher estimates. It’s we, retail investors, who should apply MOS, as we don’t know the ins and outs of the company.

77

Kwality Pharma Ltd.

  1. High-Value Regulatory Pivot & “Out-licensing” Model
  2. Massive Capacity Expansion & Imminent Utilization in biologics & hormones
  3. Margin Expansion & Financial Discipline

Disc.- Invested for long term

3 Likes
78

Existing capacity can take sales to INR 1,000 cr.

Capacity expansion is being done through internal accruals - no/minimal debt. New capacity (Biologics) will take it to 1,500 cr turnover - please refer to the last AGM video - Aditya Arora mentions that Biologics will be 500 cr plus. they have not accounted for Biologics in the 1,000 cr guidance for FY 29.

2 Likes
79

Thanks for sharing this. I am just copying the summary generated by Comet Browser here. Hope you find it useful.

Kwality Pharma looks like a niche, high-ROCE, export-focused injectables player aiming to scale from ~mid-size today to a ₹1,000+ crore revenue, ~30% EBITDA business by FY29, with most capital intensity front‑loaded and guided PAT of ~₹100 crore by FY27.[youtube]​

Snapshot: Business and Positioning

  • Core: Injectables and oral solids, oncology, cephalosporin, beta-lactam, hormones; largely export driven with domestic as a small, higher-margin oncology niche.[youtube]​

  • Model:

    • Out-licensing in RoW (dossiers and brands owned by Kwality, sold via distributors).

    • CDMO for Europe (added as alternate site to existing dossiers).

    • Biosimilars/biologics (big optionality, not in base guidance).[youtube]​

  • Edge: Multiple specialized plants, 800–900 products registered globally, strong regulatory machinery, and willingness to do bioequivalence (BE) where many Indian peers hesitate.[youtube]​

Numbers and Timelines: FY27–FY29

  • FY27 revenue:

    • Guided: at least ₹650 crore, internal range ₹650–700 crore.[youtube]​

    • Key growth drivers:

      • Mexico, Colombia, Algeria: ₹150–200 crore incremental by FY27.[youtube]​

      • Better utilization in injectables and general tablets, oncology expansion, early hormone ramp-up.

  • FY27 profitability:

    • PAT: management explicitly guides to ~₹100 crore and calls it “100% expected.”[youtube]​

    • EBITDA margin: ~25–26% at ₹650 crore sales.[youtube]​

  • FY29 ambition (implied, not always hard-guided):

    • Revenue: ~₹1,000 crore (management repeatedly links margin targets to this level).[youtube]​

    • Geography: Mexico/Colombia/Algeria alone could be ₹600–700 crore combined if 50% success rate on registrations plays out.[youtube]​

    • EBITDA margin: ~29–30% at that scale.[youtube]​

Capacity / Segment Targets by FY28–29

  • Oncology: Three new lyophilizers; management talks of ~₹500 crore oncology sales potential by FY29.[youtube]​

  • Cephalosporin + beta-lactam: ~₹200 crore by FY28.[youtube]​

  • Hormones (Unit 6): Commercial around Sep–Oct 2026; ~₹200 crore revenue potential by FY28–29.[youtube]​

  • Biosimilars: Very large capacity but kept out of formal revenue guidance due to pricing/regulatory uncertainty post patent expiries (around 2028+).[youtube]​

R&D and Product Engine

  • R&D intensity:

    • Historically ~2% of sales; targeted 5–6% by FY27 to fund pipeline.[youtube]​

  • BE pipeline:

    • Targeting ~40 BE molecules, aiming to be first/second generic in RoW and in some cases Europe.[youtube]​

    • Plan to complete 60–70 BE studies before end-FY28 to support FY29 revenue.[youtube]​

  • Organization:

    • ~80-person R&D/regulatory team for out-licensing (doctors, pharma specialists, dossier experts).[youtube]​

    • Biosimilar science largely outsourced (US cell lines, Gujarat scale-up, Kwality for final production).[youtube]​

Capex, Balance Sheet, and Working Capital

  • Capex FY27–28: ~₹160–170 crore in total.[youtube]​

    • ~₹60 crore hormones plant.

    • ~₹40 crore oncology expansion.

    • ~₹20 crore for BE work (plant-related).

    • ~₹40–50 crore for biosimilar clinicals and related plant over FY27–28.[youtube]​

  • Funding: Largely internal accruals; management mentions only ~₹10–15 crore possible additional debt if cash flows disappoint.[youtube]​

  • Working capital:

    • Currently >200 days, driven by ~150 debtor days (sea shipments, long approval cycles in importing countries).[youtube]​

    • Aim: improve to ~170–180 days by pushing more business to Mexico/Colombia with faster payments and more air shipments.[youtube]​

    • Inventory days already starting to decline as mix and throughput improve.[youtube]​

Governance, Capital Allocation, and “Soft” Factors

  • Governance / comfort:

    • Plan to appoint KPMG as statutory auditor, likely from next financial year.[youtube]​

    • Current “issuer not cooperating” rating is due to company not pursuing rating; they indicate willingness to get a proper rating next year.[youtube]​

  • Listing and shareholder returns:

    • No dividend/bonus until scale and capex cycle are largely done; they explicitly say payouts are post-₹1,000 crore revenue and post capex (i.e., after FY29).[youtube]​

    • NSE main-board listing considered around FY29.[youtube]​

  • Track record vs guidance:

    • Acknowledge minor miss vs earlier quarterly topline guidance (₹124 crore vs ~₹140 crore earlier indication), attributing ~₹10–15 crore to holiday-season shipping delays.[youtube]​

    • Stress that FY27 PAT ₹100 crore is realistic and already visible in the orderbook/pipeline.[youtube]​

Risk–Reward Cheat-Sheet

Key positives (what’s interesting):

  • High-margin export injectables/orals franchise with strong RoW presence and growing European CDMO leg.[youtube]​

  • Clear 3-year visibility: guided path to ₹650+ crore revenue and ~₹100 crore PAT by FY27, with detailed plant- and geography-level levers.[youtube]​

  • Operating leverage: multiple underutilized blocks (general tablets, some injectables) that can sweat with the 40 BE products and new registrations.[youtube]​

  • Optionality from biosimilars and hormones not fully baked into near-term guidance, giving upside if execution is strong.[youtube]​

  • Management appears aggressive but numerate on capex sizing and debt discipline (prefers internal accruals, low incremental borrowing).[youtube]​

Key risks / things to track:

  • Regulatory and registration risk: main execution bottleneck is speed of ministry/authority responses; even with strong dossiers, approvals can be slow and lumpy.[youtube]​

  • Working-capital drag: 170–200+ day cycle structurally keeps cash tied up; thesis requires improvement via better geography/product mix.[youtube]​

  • Concentration in a few new markets: a lot of FY27–29 growth narrative leans on Mexico/Colombia/Algeria ramping as planned.[youtube]​

  • Biosimilar uncertainty: patents, pricing pressure, and regulatory timelines can significantly shift economics vs current assumptions.[youtube]​

  • Execution stretch: managing six plants, 800–900 products, and 60–70 BE studies while scaling governance (big-4 auditor, rating, listing) is operationally demanding.[youtube]​

Invested and Biased.

2 Likes
80

In the call they also mentioned new markets like South East Asia. Export market is so large that 1,000 cr sales is not difficult at all.

Kwality has been successful in getting many regulatory approvals (even European) which shows their products are good. they have capacity to meet the 1,000cr target and also adding capacity to go beyond that.

1 Like
81

Plant / Site Visit to Kwality Pharmaceutical Ltd, organised by Go India Advisors. Registration link- GoIndiaStocks - Unbiased & Balanced

2 Likes
82

Would you i have been pushing the stock.. if yes thanks.. it has gone up from 300 to 1500.

2 Likes
83

one should visit Kwality pharma’s plants. My colleague has visited and found the plants very good.. and you can see for yourself the expansion which is happening.

1 Like
84

Analysis of today’s Announcement**

*BE program covers 30+ molecules, Completing Phase 1 validates KPL’s capabilities.

*The successful study of Liposomal Amphotericin B is particularly significant. Liposomal formulations are complex injectables with high entry barriers and superior pricing power compared to conventional generics.

https://www.bseindia.com/xml-data/corpfiling/AttachLive/ca1468fc-601a-4471-8001-1557a31f0037.pdf

85

Arihant Bharat Connect Conference: Rising Stars 2026 Link

Notes:

Financial guidance and outlook

FY26: Closing near ₹500 crore revenue (9M at ₹346 crore implied); FY27: ₹650 crore revenue, >₹100 crore PAT; FY29: ₹1,000–1,100 crore (~30% CAGR), EBITDA margins 26–30% via oncology mix shift.
​Country contributions (9M FY26): Algeria $5M, Mexico $1.5–2M, Colombia $2–3M, Venezuela $8–9M, Peru/Guatemala etc. $3M, Iraq/Kurdistan $8–9M, Africa $5–6M, domestic ₹40–50 crore, SE Asia $4M, Russia ramping Q4.
​Working capital: Debtor/inventory days high but stable Q4 FY26; potential improvement Q2 FY27 via air shipments to LATAM; no major worsening expected despite Red Sea delays (adding 20–30 days).

Product Development & Regulatory Pipeline

The company has developed 600–700 dossiers for products targeted at semi-regulated and unregulated markets.

  • These dossiers are being filed across:

    • LATAM

    • CIS countries

    • Southeast Asia

  • As registrations mature, management expects continued growth.

Bio-equivalence Pipeline

  • 40–45 bio-equivalence studies underway.

  • These will enable:

    • More product registrations globally

    • Entry into regulated markets like Europe.

Biosimilar Development

  • Key targets:

    • 1 clinical study completion

    • 3 new cell line developments

  • Target completion by 2027.

4 Likes
86

With Bioequivalence studies being successful, they can increase sales to regulated markets at high margins. Once US FDA approval (for vet products) is obtained sales and margins will improve further. I hope they go for US FDA for human drugs as well which will open a huge market for the company.

One important point is company has not factored in sales from Biologics business in the guidance given. they are increasing capacity of Biologics from 100KL to 600KL. this it self can add 500cr sales (was mentioned by Aditya Arora in AGM). So if we include biologics sales can go up 1,500 cr and so EBITDA at 450 Cr (30% margin)… PAT of ~300cr. mkt cap 6,000 cr.

Request others to share their views on the numbers i have projected. thanks.

PS - once mutual funds start investing this stock will get rerated.

2 Likes
87

Promoters still buying.. small lots.

image
image680×620 72.2 KB

1 Like